KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1-49%

Research output: Contribution to journal › Comment/debate

Access to Document

@article{9ca563abd3b641c7b56faa442c3c03f2,

title = "KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1-49%",

author = "Daniel Morgensztern",

year = "2019",

doi = "10.21037/jtd.2019.07.80",

language = "English",

volume = "11",

pages = "S1963--S1965",

journal = "Journal of Thoracic Disease",

issn = "2072-1439",

}

TY - JOUR

T1 - KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1-49%

AU - Morgensztern, Daniel

PY - 2019

Y1 - 2019

UR - http://www.scopus.com/inward/record.url?scp=85073783432&partnerID=8YFLogxK

U2 - 10.21037/jtd.2019.07.80

DO - 10.21037/jtd.2019.07.80

M3 - Comment/debate

C2 - 31632798

AN - SCOPUS:85073783432

SN - 2072-1439

VL - 11

SP - S1963-S1965

JO - Journal of Thoracic Disease

JF - Journal of Thoracic Disease

ER -